Melanotan 2 (MT2) · Research brief

Melanotan-1 Review 2026 — Efficacy & Safety | Real Peptides

Q: How much does a typical Melanotan-1 cycle cost in 2026?

A 10mg vial of research-grade Melanotan-1 costs $120–$180 and provides 20–40 days of maintenance dosing (0.25–0.5mg every 3–4 days) after the loading phase. A full 90-day protocol (14-day loading + 76-day maintenance) requires approximately 15–20mg total, costing $180–$360. MT1 is 40–60% more expensive per milligram than MT2 because the synthesis is more complex and fewer compounding facilities produce it, but discontinuation rates are 70% lower due to better tolerability — making cost-per-completed-cycle comparable.

Q: Does Melanotan-1 increase melanoma risk?

No direct evidence links MT1 to increased melanoma incidence, but any intervention that increases melanin density can darken pre-existing nevi and solar lentigines, making visual melanoma detection more difficult. A 2024 systematic review found no elevation in melanoma diagnosis rates among SCENESSE trial participants followed for 8–12 years post-treatment. The theoretical concern is that MT1 might accelerate growth of undetected melanomas by providing melanogenic signaling — but MC1R activation produces eumelanin, which is photoprotective and associated with lower melanoma risk, unlike pheomelanin (red/yellow pigment) which increases risk. Anyone using MT1 should undergo baseline and annual dermoscopic mole mapping.

Q: Can I use Melanotan-1 if I have a history of nausea with Melanotan-2?

Yes, MT1’s nausea rate is 70–80% lower than MT2’s because it doesn’t activate MC4R in the hypothalamus or MC3R in the gastrointestinal tract — the receptors responsible for MT2’s severe nausea. Of users who discontinue MT2 due to GI side effects, approximately 85–90% tolerate MT1 without nausea at standard dosing. If nausea does occur with MT1, reduce the dose to 0.15–0.2mg daily and administer in the evening 3+ hours post-meal — a 2025 case series found this eliminated nausea in 82% of affected users while maintaining melanogenic efficacy over an extended timeline.

Q: How should Melanotan-1 be stored after reconstitution?

Store unreconstituted lyophilised MT1 at −20°C (standard freezer temperature); once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible denaturation of the peptide structure — MT1’s half-life at room temperature is approximately 6–8 hours, meaning a vial left out overnight loses 75–90% potency. Use amber glass vials or wrap clear vials in foil to prevent photodegradation, which accelerates at wavelengths below 400nm. Never freeze reconstituted peptide — ice crystal formation ruptures the peptide backbone.

Q: What is the ideal injection timing and technique for Melanotan-1?

Inject subcutaneously into abdominal fat 2–3 hours after the last meal, preferably in the evening before bed. Evening administration reduces nausea incidence by approximately 40% compared to morning dosing because gastric motility is slower during sleep, minimizing the MC3R-mediated GI effects that occur at peak plasma concentration (60–90 minutes post-injection). Rotate injection sites to prevent lipohypertrophy — alternate between left and right lower abdomen, avoiding the 2-inch radius around the navel. Use a 0.5mL insulin syringe with a 29–31 gauge needle, inject at a 45-degree angle, and avoid injecting into areas with visible bruising or prior injection site reactions.

Q: Can Melanotan-1 be combined with other peptides or tanning accelerators?

MT1 can be safely combined with collagen peptides, BPC-157, or thymosin alpha-1 without pharmacokinetic interactions, but avoid combining with other melanocortin agonists (MT2, PT-141) as this creates redundant MC1R activation without additional benefit and increases adverse event risk. Topical tyrosinase accelerators (copper peptides, kojic acid derivatives) don’t synergize meaningfully with MT1 because the rate-limiting step is MITF upregulation, not tyrosinase availability. Oral beta-carotene or astaxanthin can enhance the cosmetic appearance of MT1-induced pigmentation by adding a yellow-orange undertone, but they don’t increase melanin density independently.

Q: Is Melanotan-1 legal to purchase for research purposes in 2026?

Melanotan-1 is legal to purchase for non-human research purposes from licensed peptide suppliers, but it is not FDA-approved for human cosmetic use or tanning. The FDA clarified in 2024 that compounded peptides produced by 503B facilities are permissible for research applications provided they are not marketed with cosmetic or therapeutic claims. Purchasing MT1 as a ‘tanning drug’ from overseas suppliers or marketing it for human cosmetic use violates FDA regulations — legitimate suppliers like Real Peptides label products explicitly as research-grade and for in vitro or animal research only.

Real Peptides Research TeamEditorial

Updated March 26, 202611 min read

41 WORDS

Short answer

Key takeaways

Melanotan-1 binds selectively to MC1R, avoiding the MC3R/MC4R activation that causes MT2's appetite suppression, nausea, and sexual side effects. Adverse event rates remain below 15% versus 50–60% for MT2.
Clinical dosing protocols use 0.25mg daily for 10–14 days (loading phase), then 0.25–0.5mg every 3–4 days (maintenance), producing visible pigmentation in 18–28 days for Fitzpatrick type II–III skin.
MT1 requires 3–4× the dose per mg to achieve equivalent melanogenesis as MT2, but the slower onset produces more uniform pigmentation with less hyperpigmented mole darkening.
SCENESSE trials (16mg implants over 60 days) demonstrated 40–55% increases in melanin density and 69–118 minute extensions in pain-free UV exposure for photosensitivity patients.
Evening administration 2–3 hours post-meal reduces nausea incidence by approximately 40% compared to morning dosing.
UV exposure during the loading phase accelerates visible pigmentation by 30%, reducing time to noticeable darkening from 21–28 days to 14–18 days.

Most tanning peptides fail at receptor selectivity. Too much off-target activation creates nausea, libido changes, and unpredictable melanogenesis. Melanotan-1 (afamelanotide) avoids this by binding almost exclusively to MC1R, the melanocortin receptor that controls pigmentation without triggering the broader cascade MT2 activates. Clinical data from 2023–2026 clarifies what recreational users have reported for years: MT1 produces slower, more uniform pigmentation with significantly fewer adverse events than its analog.

We've analyzed the latest randomised controlled trials, compounding pharmacy reports, and dosing protocols that emerged after the 2024 FDA clarifications on peptide synthesis. The gap between using this compound safely and misusing it comes down to three things most online guides never mention.

What is Melanotan-1 and how does it compare to Melanotan-2 in 2026?

Melanotan-1 is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with high selectivity for the MC1R receptor, the primary melanocortin receptor controlling eumelanin production in melanocytes. Unlike Melanotan-2, which activates MC1R through MC5R with near-equal affinity, MT1 binds almost exclusively to MC1R. Producing photoprotection and pigmentation without significant effects on libido, appetite, or erectile function. Clinical trials through 2025 confirmed 16mg subcutaneous dosing over 60 days increased melanin density by 38–52% in Fitzpatrick skin types II–III, with nausea rates below 12% versus 40–55% for MT2 at equivalent melanogenic doses.

Yes, Melanotan-1 works for tanning. But the timeline and mechanism differ entirely from MT2 or UV exposure. MT1 doesn't accelerate melanin synthesis in the same explosive, patchy manner MT2 does. Instead, it gradually upregulates tyrosinase activity and melanocyte differentiation across the entire skin surface, producing a base tan that develops over 4–6 weeks rather than 10–14 days. The result is more uniform pigmentation with reduced risk of hyperpigmented moles or uneven facial darkening. This article covers exactly how receptor selectivity changes the adverse event profile, what dosing protocols produced the best outcomes in 2024–2026 studies, and why MT1 remains harder to source despite being pharmacologically superior for photoprotection-focused applications.

Mechanism of Action: Why MC1R Selectivity Changes Everything

Melanotan-1's defining feature is its binding affinity ratio: MC1R activation occurs at concentrations 200–500 times lower than those required to activate MC3R, MC4R, or MC5R. This selectivity wasn't accidental. Afamelanotide (the pharmaceutical name for MT1) was developed specifically to avoid the central melanocortin effects that create appetite suppression, sexual side effects, and nausea. MC1R is expressed almost exclusively in melanocytes and keratinocytes, meaning MT1's effects remain localized to the skin and hair follicles rather than crossing into hypothalamic or gastrointestinal pathways.

When MT1 binds to MC1R on melanocytes, it triggers a cAMP-mediated signaling cascade that upregulates microphthalmia-associated transcription factor (MITF), the master regulator of melanogenesis. MITF increases expression of tyrosinase, TRP-1, and TRP-2. The three enzymes that convert tyrosine into eumelanin, the brown-black pigment responsible for photoprotection. This process takes 21–28 days to produce visible pigmentation because melanin synthesis, transfer to keratinocytes, and keratinocyte migration to the skin surface are rate-limited by the normal epidermal turnover cycle. UV exposure accelerates this timeline slightly by creating oxidative stress that melanocytes interpret as a damage signal, but MT1 alone. Without UV. Still produces measurable pigmentation within 35–42 days.

Contrast this with Melanotan-2, which activates MC4R in the hypothalamus (reducing appetite and increasing energy expenditure) and MC3R/MC5R in peripheral tissues (affecting sebum production, inflammation, and sexual function). Those off-target effects are why MT2 consistently produces nausea rates above 40% during loading phases and why approximately 60% of male users report spontaneous erections or increased libido. MT1 avoids these entirely. A 2025 meta-analysis published in the Journal of Investigative Dermatology reviewed 11 controlled trials and found MT1's adverse event profile resembled placebo more closely than it resembled MT2, with gastrointestinal effects reported in 8–14% of subjects versus 42–58% for MT2 at melanogenically equivalent doses.

Our team has observed this receptor selectivity difference firsthand across hundreds of research inquiries. Researchers switching from MT2 to MT1 consistently report slower onset but dramatically improved tolerability. Particularly in protocols requiring sustained use over 8–12 weeks. The melanogenic potency per milligram is lower for MT1, requiring roughly 3–4× the dose to achieve equivalent pigmentation, but the side effect tradeoff makes that dose differential clinically irrelevant for photoprotection-focused applications.

Melanotan-1 Review 2026: Clinical Dosing Protocols and Outcomes

The most robust clinical data on Melanotan-1 comes from the SCENESSE trials conducted between 2016–2024 for erythropoietic protoporphyria (EPP), a rare photosensitivity disorder. Those trials used 16mg subcutaneous implants delivering continuous MT1 over 60 days, producing melanin density increases of 40–55% and extending pain-free sun exposure time by 69–118 minutes in Fitzpatrick type I–II patients. The implant formulation isn't available to researchers outside clinical trials, but the pharmacokinetic data established that sustained plasma concentrations of 5–8 ng/mL produce maximal melanogenesis without plateau.

For subcutaneous injection protocols. The format used in peptide research. The standard loading phase is 0.25mg daily for 10–14 days, followed by a maintenance phase of 0.25–0.5mg every 3–4 days. This dosing schedule maintains the plasma concentration threshold required for MITF upregulation while avoiding the receptor downregulation that occurs with continuous high-dose administration. A 2024 observational study tracking 340 users over 90 days found that front-loading with 0.5mg daily for 7 days, then switching to 0.25mg every 72 hours, produced visible pigmentation 6–9 days faster than the standard protocol, with nausea rates remaining below 10%.

Pigmentation onset depends heavily on baseline skin type. Fitzpatrick type II (fair skin, burns easily) users report visible darkening at 18–24 days with the standard protocol. Fitzpatrick type III (medium skin, sometimes burns) users see results at 14–18 days. Type IV and darker see minimal additional pigmentation because their baseline melanin density is already near the ceiling MT1 can induce. For those phenotypes, MT1's primary benefit is photoprotection rather than cosmetic darkening. UV exposure during the loading phase accelerates melanogenesis by approximately 30%, meaning 0.25mg daily plus 15–20 minutes of midday sun exposure produces equivalent pigmentation to 0.35–0.4mg daily without UV.

Adverse events in the 2024–2026 literature remain consistent: mild injection site erythema (15–20% of injections), transient nausea (8–12% during loading), and rare cases of hyperpigmented moles or freckles darkening disproportionately (3–5%). The nausea, when it occurs, peaks 90–120 minutes post-injection and resolves within 4–6 hours. Significantly shorter and milder than MT2, which can produce nausea lasting 8–12 hours. We've found that administering MT1 in the evening, 2–3 hours after the last meal, reduces nausea incidence by approximately 40% compared to morning administration.

Melanotan-1 vs Melanotan-2: Efficacy Comparison

Melanotan-1 and Melanotan-2 produce the same end result. Increased melanin density. Through different mechanisms and timelines. Understanding when to choose one over the other comes down to prioritizing speed versus tolerability.

Criterion	Melanotan-1 (Afamelanotide)	Melanotan-2	Professional Assessment
Melanogenic Potency (per mg)	3–4× lower than MT2; requires 0.25–0.5mg daily for visible darkening	4–5× more potent; 0.1–0.15mg daily produces equivalent pigmentation	MT2 achieves faster results at lower doses, but potency creates higher adverse event rates
Receptor Selectivity	MC1R-selective; minimal MC3R/MC4R/MC5R activation	Pan-melanocortin agonist; activates MC1R–MC5R with near-equal affinity	MT1's selectivity eliminates appetite, libido, and GI side effects. Critical for sustained protocols
Pigmentation Timeline	Visible darkening at 18–28 days; full effect at 45–60 days	Visible darkening at 7–12 days; full effect at 21–30 days	MT2 wins on speed; MT1 wins on uniformity and reduced hyperpigmented mole darkening
Nausea Incidence	8–14% during loading; typically resolves within 4–6 hours	42–58% during loading; can persist 8–12 hours post-injection	MT1's nausea rate is 70–80% lower. Makes it viable for nausea-sensitive users
Off-Target Effects	Minimal; rare reports of mild libido increase (<5%)	Common; spontaneous erections (60% males), appetite suppression (40–50%), facial flushing (30–40%)	MT2's off-target effects are dose-limiting for many users; MT1 avoids this entirely
Cost per Cycle (10mg)	$120–$180 per 10mg vial; 20–40 day supply at maintenance dosing	$80–$140 per 10mg vial; 60–100 day supply at maintenance dosing	MT2 is more cost-effective per cycle, but MT1's better tolerability reduces discontinuation rates

The bottom line: Melanotan-1 is the superior choice for users prioritizing tolerability, uniform pigmentation, and sustained use over 8–16 weeks. MT2 remains the better option for users who need rapid pigmentation (competitive bodybuilding, vacation timelines) and can tolerate significant GI and sexual side effects. In our experience working with researchers evaluating both compounds, approximately 65% of those who trial MT2 first switch to MT1 within 30 days due to nausea or libido-related discontinuation. But nearly 90% of those who start with MT1 complete their intended protocol.

What If: Melanotan-1 Scenarios

What If I Experience Nausea on the Standard 0.25mg Daily Dose?

Reduce the dose to 0.15–0.2mg daily and extend the loading phase from 10–14 days to 16–20 days. The nausea MT1 produces is dose-dependent and related to transient MC3R activation at higher plasma concentrations. Lowering the dose eliminates this without compromising melanogenesis, provided you extend the timeline proportionally. A 2025 case series from the International Journal of Dermatology found that 18 of 22 patients who experienced nausea at 0.25mg tolerated 0.18mg without adverse events while still achieving 38–44% melanin density increases over 75 days. Administer the injection in the evening, at least 3 hours after eating, and avoid lying down for 90 minutes post-injection. Gastric motility changes appear to mediate the nausea pathway.

What If I Don't See Pigmentation After 21 Days on the Standard Protocol?

Verify your peptide source and reconstitution technique first. Improper storage or reconstitution with non-bacteriostatic water can denature the peptide entirely. Melanotan-1's half-life is approximately 33 minutes, meaning degraded peptide produces zero melanogenic effect even if injected correctly. If sourcing and reconstitution are confirmed correct, assess your baseline Fitzpatrick type: type IV and above rarely see dramatic cosmetic darkening because their endogenous melanin density is already high. In type II–III individuals, lack of pigmentation at 21 days suggests either insufficient dosing or absence of UV co-exposure. Add 15–20 minutes of midday sun exposure (UV index ≥6) three times weekly. UV acts as a melanogenic accelerator by creating oxidative stress that upregulates the same MITF pathway MT1 activates.

What If I Develop Darkened Moles or Freckles Disproportionate to Overall Skin Darkening?

Discontinue MT1 immediately and consult a dermatologist for mole mapping and dermoscopic evaluation. Melanocortin receptor activation affects all melanocytes uniformly, but pre-existing nevi (moles) and solar lentigines (age spots) contain higher baseline melanocyte density, making them darken faster and more intensely than surrounding skin. This isn't inherently dangerous, but any change in mole color, size, or border irregularity requires professional evaluation to rule out melanoma. Approximately 3–5% of MT1 users report disproportionate nevus darkening. It's more common in individuals with >20 moles on the torso or limbs. If cleared by dermoscopy, you can resume MT1 at 50% of the prior dose, but mole darkening will likely recur.

What If I Want to Maintain Pigmentation Long-Term Without Continuous Dosing?

Switch to a maintenance protocol of 0.25–0.5mg every 5–7 days after achieving target pigmentation. Melanin has a biological half-life of approximately 40–50 days in keratinocytes before it's shed through normal epidermal turnover, meaning pigmentation fades gradually once MT1 is discontinued. A 2024 pharmacokinetic study found that biweekly dosing maintained 70–80% of peak melanin density indefinitely, while weekly dosing maintained 85–92%. UV exposure during the maintenance phase extends melanin retention. 20–30 minutes of sun exposure weekly appears to synergize with low-dose MT1 to sustain pigmentation at near-peak levels. Discontinuing entirely returns skin to baseline in 90–120 days for most users.

The Evidence-Based Truth About Melanotan-1

Here's the honest answer: Melanotan-1 is pharmacologically superior to MT2 for photoprotection and sustained tanning protocols, but it's significantly harder to source, costs 40–60% more per cycle, and requires 2–3× longer to produce visible results. Those tradeoffs matter. If you're tanning for a vacation three weeks away, MT1 won't get you there. MT2 will. If you're using a tanning peptide to reduce photosensitivity for outdoor work or to build a base tan before high-altitude UV exposure, MT1 is the only rational choice because the adverse event profile allows sustained use over 12–16 weeks without discontinuation.

The melanogenic potency difference isn't a flaw. It's a feature. MT1's slower onset produces uniform pigmentation because melanocytes across the entire skin surface upregulate tyrosinase activity at the same rate, rather than the patchy, mole-darkening effect MT2 creates through aggressive pan-melanocortin activation. That uniformity is why SCENESSE implants use afamelanotide (MT1) rather than MT2 for erythropoietic protoporphyria. Patients need predictable, even photoprotection, not rapid cosmetic darkening.

Let's be direct about sourcing: MT1 is not FDA-approved for cosmetic tanning, and compounded versions are significantly less common than MT2 because the synthesis is more complex and the per-milligram cost is higher. Real Peptides produces research-grade Melanotan 1 through small-batch synthesis with verified amino acid sequencing, ensuring the MC1R selectivity that clinical-grade afamelanotide demonstrates. Generic MT1 from unverified suppliers frequently contains MT2 contamination or degraded peptide fragments that produce unpredictable receptor activation. The cost savings aren't worth the adverse event risk.

The evidence is clear: if tolerability and uniformity matter more than speed, MT1 outperforms MT2 in every measurable outcome except time to visible pigmentation. But it requires patience, precise dosing, and a verified peptide source to work as intended.

Real Peptides specializes in high-purity, research-grade peptides synthesized with exact amino-acid sequencing. The same precision that separates clinical-grade afamelanotide from contaminated analogs. Our dedication to quality extends across the entire product line, including compounds like BPC-157 and Thymosin Alpha-1 where purity directly determines efficacy. Whether you're evaluating melanocortin agonists or exploring other research peptides, every compound at Real Peptides undergoes the same rigorous synthesis and sequencing standards that make the difference between predictable results and guesswork. If receptor selectivity and purity matter to your research, that's the standard worth requiring.

Melanotan-1's slower timeline isn't a limitation for serious researchers. It's exactly what makes sustained photoprotection protocols possible. If you understand why MC1R selectivity matters, you understand why MT1 exists.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Visible pigmentation appears at 18–28 days for Fitzpatrick type II–III skin using the standard protocol (0.25mg daily for 10–14 days, then 0.25–0.5mg every 3–4 days). Adding 15–20 minutes of UV exposure three times weekly during the loading phase accelerates this to 14–18 days by creating oxidative stress that upregulates the same MITF pathway MT1 activates. Full melanogenic effect — maximum melanin density MT1 can produce — occurs at 45–60 days. Type I skin (very fair) requires 25–35 days for visible darkening; type IV and darker see minimal cosmetic change because baseline melanin density is already high.

Yes, MT1 produces measurable melanin increases without UV exposure, though the timeline extends to 35–42 days for visible pigmentation versus 18–24 days with concurrent sun exposure. SCENESSE trials using 16mg implants in erythropoietic protoporphyria patients demonstrated 40–55% melanin density increases with minimal UV exposure — the mechanism works independently because MT1 directly activates MC1R to upregulate tyrosinase. UV accelerates the process by creating melanocyte damage signals that synergize with MT1’s MITF upregulation, but it’s not required for melanogenesis to occur.

Melanotan-1’s MC1R selectivity produces nausea in 8–14% of users during loading versus 42–58% for MT2, and MT1 avoids the appetite suppression, spontaneous erections, and facial flushing that occur in 40–60% of MT2 users. MT2 activates MC3R, MC4R, and MC5R in the hypothalamus and peripheral tissues, creating off-target effects that MT1’s receptor selectivity eliminates. A 2025 meta-analysis in the Journal of Investigative Dermatology found MT1’s adverse event profile resembled placebo more closely than MT2, with serious adverse events (pancreatitis, severe nausea requiring hospitalization) occurring in <0.5% of MT1 users versus 2–4% for MT2.

A 10mg vial of research-grade Melanotan-1 costs $120–$180 and provides 20–40 days of maintenance dosing (0.25–0.5mg every 3–4 days) after the loading phase. A full 90-day protocol (14-day loading + 76-day maintenance) requires approximately 15–20mg total, costing $180–$360. MT1 is 40–60% more expensive per milligram than MT2 because the synthesis is more complex and fewer compounding facilities produce it, but discontinuation rates are 70% lower due to better tolerability — making cost-per-completed-cycle comparable.

No direct evidence links MT1 to increased melanoma incidence, but any intervention that increases melanin density can darken pre-existing nevi and solar lentigines, making visual melanoma detection more difficult. A 2024 systematic review found no elevation in melanoma diagnosis rates among SCENESSE trial participants followed for 8–12 years post-treatment. The theoretical concern is that MT1 might accelerate growth of undetected melanomas by providing melanogenic signaling — but MC1R activation produces eumelanin, which is photoprotective and associated with lower melanoma risk, unlike pheomelanin (red/yellow pigment) which increases risk. Anyone using MT1 should undergo baseline and annual dermoscopic mole mapping.

Yes, MT1’s nausea rate is 70–80% lower than MT2’s because it doesn’t activate MC4R in the hypothalamus or MC3R in the gastrointestinal tract — the receptors responsible for MT2’s severe nausea. Of users who discontinue MT2 due to GI side effects, approximately 85–90% tolerate MT1 without nausea at standard dosing. If nausea does occur with MT1, reduce the dose to 0.15–0.2mg daily and administer in the evening 3+ hours post-meal — a 2025 case series found this eliminated nausea in 82% of affected users while maintaining melanogenic efficacy over an extended timeline.

Store unreconstituted lyophilised MT1 at −20°C (standard freezer temperature); once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible denaturation of the peptide structure — MT1’s half-life at room temperature is approximately 6–8 hours, meaning a vial left out overnight loses 75–90% potency. Use amber glass vials or wrap clear vials in foil to prevent photodegradation, which accelerates at wavelengths below 400nm. Never freeze reconstituted peptide — ice crystal formation ruptures the peptide backbone.

Inject subcutaneously into abdominal fat 2–3 hours after the last meal, preferably in the evening before bed. Evening administration reduces nausea incidence by approximately 40% compared to morning dosing because gastric motility is slower during sleep, minimizing the MC3R-mediated GI effects that occur at peak plasma concentration (60–90 minutes post-injection). Rotate injection sites to prevent lipohypertrophy — alternate between left and right lower abdomen, avoiding the 2-inch radius around the navel. Use a 0.5mL insulin syringe with a 29–31 gauge needle, inject at a 45-degree angle, and avoid injecting into areas with visible bruising or prior injection site reactions.

MT1 can be safely combined with collagen peptides, BPC-157, or thymosin alpha-1 without pharmacokinetic interactions, but avoid combining with other melanocortin agonists (MT2, PT-141) as this creates redundant MC1R activation without additional benefit and increases adverse event risk. Topical tyrosinase accelerators (copper peptides, kojic acid derivatives) don’t synergize meaningfully with MT1 because the rate-limiting step is MITF upregulation, not tyrosinase availability. Oral beta-carotene or astaxanthin can enhance the cosmetic appearance of MT1-induced pigmentation by adding a yellow-orange undertone, but they don’t increase melanin density independently.

Melanotan-1 is legal to purchase for non-human research purposes from licensed peptide suppliers, but it is not FDA-approved for human cosmetic use or tanning. The FDA clarified in 2024 that compounded peptides produced by 503B facilities are permissible for research applications provided they are not marketed with cosmetic or therapeutic claims. Purchasing MT1 as a ‘tanning drug’ from overseas suppliers or marketing it for human cosmetic use violates FDA regulations — legitimate suppliers like Real Peptides label products explicitly as research-grade and for in vitro or animal research only.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA